



NECESSITY REPORT TO ESTABLISH THE CONTRACTING OF A SERVICE PROVIDER OF A COMPREHENSIVE TOOL FOR GENOMIC ANALYSIS AND ONLINE BIOLOGICAL DATA INTERPRETATION OF PEDIATRIC TUMORS FOR THE CHILDHOOD CANCER AND HEMATOLOGIC DISEASES GROUP OF THE FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR).

"PI21/01661" titled "COMIK v2.0: Integration of Functional and Genomic Screening in a Personalized Medicine Program for Childhood Cancer." This study has been funded by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Union.



"PMP21/00073" titled "SEHOP-PENCIL - National strategy for the implementation of personalized medicine in children and adolescents with cancer." This project has been funded by the Instituto de Salud Carlos III and the European Union Next Generation EU/PRTR.



"ICI21/00076" titled "Phase I trial of ABTL0812 in children with relapsed or refractory neuroblastoma and extracranial solid tumors." This project has been funded by the Instituto de Salud Carlos III and the European Union Next Generation EU/PRTR.



"PI24/01576" titled "Incorporation of targeted therapies and immunotherapy for treatment of children and adolescents with relapsed neuroblastoma with a deep biological characterization and development of the BEACON2 trial." This study has been funded by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Union.



## 2025-GENOMIC ANALYSIS OF PEDIATRIC TUMORS

Dr. Lucas Moreno Martín-Retortillo, Head of the Childhood Cancer and Blood Disorders Group of the Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca, proposes that the corresponding file be included for the contracting of the service of a comprehensive tool for genomic analysis and online interpretation of data derived from Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES) and RNA sequencing (RNAseq) of tumor samples of pediatric patients and patient-derived xenograft (PDX) models, by the projects:

 PI21/01661 titled "COMIK v2.0: Integration of Functional and Genomic Screening in a Personalized Medicine Program for Childhood Cancer." This study has been funded by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Union.







- PMP21/00073 titled "SEHOP-PENCIL-National strategy for the implementation of personalized medicine in children and adolescents with cancer." This project has been funded by the Instituto de Salud Carlos III and the European Union Next Generation EU/PRTR.
- ICI21/00076 titled "Phase I trial of ABTL0812 in children with relapsed or refractory neuroblastoma and extracranial solid tumors." This project has been funded by the Instituto de Salud Carlos III and the European Union Next Generation EU/PRTR.
- PI24/01576 titled "Incorporation of targeted therapies and immunotherapy for treatment of children and adolescents with relapsed neuroblastoma with a deep biological characterization and development of the BEACON2 trial." This study has been funded by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Union.

intended for the research group "Childhood Cancer and Blood Disorders" of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), as stipulated in the present Technical Specifications.

The Childhood Cancer and Blood Disorders Group does not have a comprehensive tool for the genomic analysis and online biological data interpretation of WGS, WES and RNAseq data, and therefore must outsource this service to an external provider

This tender is not divided into lots because it is related to only one service, which is the genomic analysis and online biological data interpretation of WGS, WES and RNAseq data from tumor samples of pediatric patients and PDX models. Although the data may originate from different sequencing techniques, the genomic analysis and interpretation must be carried out in an integrated manner. To ensure consistency and comparability across all data analyzed within the projects, this service must be conducted using the same comprehensive tool.

The duration of the service object of this tender will coincide with the validity of the aforementioned projects which is, overall, until **31 December 2027**.


The service will start on the day following the formalization of the contract.

As of the date of publication of this tender, the duration of the projects is as follow:

- Project Pl21/01661 runs until 31 June 2026.
- Project PMP21/00073 is until 31 December 2025 (possible extension 31 June 2026).
- Project ICI21/00076 runs until 31 December 2025 (possible extension 31 June 2026).
- Project Pl24/01576 is until 31 December 2027.

However, if this project were to be found, for any unforeseen reasons, subject to the request of a possible extension, the end date will be susceptible to being extended, at most to the one that is finally authorized.

The service will begin on the day following the formalization of the contract.







The total maximum budget is SEVENTY-SEVEN THOUSAND FOUR HUNDRED EIGHTY-SIX EUROS AND NINETY-FIVE CENTS" (77.486,95 €) without VAT, which is financed in the following way:

- For the project PI21/01661 "COMIK v2.0", expenditure of "THIRTY-SIX THOUSAND THREE HUNDRED EIGHTY EUROS AND SIXTY CENTS" (36.380,60 EUROS) VAT excluded.
- For the project PMP21/00073 "SEHOP-PENCIL", expenditure of "NINE THOUSAND TWO HUNDRED SIXTY-THREE EUROS AND SIXTY CENTS" (9.263,60 EUROS) VAT excluded.
- For the project ICI21/00076 "ABTL0812", expenditure of "NINE THOUSAND TWO HUNDRED TEN EUROS AND SEVENTY-FIVE CENTS" (9.210,75 EUROS) VAT excluded.
- For the project PI24/01576 "BEACON2 trial", expenditure of "TWENTY-TWO THOUSAND SIX HUNDRED THIRTY-TWO EUROS" (22.632,00 EUROS) VAT excluded.

In view of all of the above,

## IT IS HEREBY DECIDED:

- 1.- To order the opening of the tender file for service provider of a comprehensive tool for genomic analysis and online biological data interpretation of pediatric tumors for the Childhood Cancer and Hematologic Diseases Group of the Fundació Hospital Universitari Vall Hebron Institut de Recerca (VHIR), the maximum budget for this tender is set at 77.486,95 € VAT exempted.
- 2.- To order the certification of the existence of sufficient credit to certify that the VHIR has a sufficient budgetary endowment to face the expenses arising from this tender file.

Barcelona, on the digital signature date.

## **RESPONSIBLE**

Dr. Lucas Moreno Martín-Retortillo
Head of the PI21/01661, PMP21/00073, ICI21/00076 and PI24/01576 projects
Head of the Childhood Cancer and Blood Disorders Group of the VHIR